Zum Hauptinhalt springen

Hepatitiden

27. Dezember 2017 | Hepatitiden

Hepatitis C antibody and RNA prevalence among opiate substituted patients in Germany: Results from the nationwide ECHO-Study

Hepatitis C antibody and RNA prevalence among opiate substituted patients in Germany: Results from the nationwide ECHO-Study Bernd Schulte, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-2…

27. Dezember 2017 | Hepatitiden

Associations of HIV and HCV with prison history among people who inject drugs in Europe and beyond

Associations of HIV and HCV with prison history among people who inject drugs in Europe and beyond Lucas Wiessing (EMCDDA), Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017 http…

27. Dezember 2017 | Hepatitiden

No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community

No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S. Lambert, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24…

27. Dezember 2017 | Hepatitiden

Hepatitis C Testing, Care and Treatment at Harm Reduction Centres in the European Union: a 28-Country Survey of Service Providers

Hepatitis C Testing, Care and Treatment at Harm Reduction Centres in the European Union: a 28-Country Survey of Service Providers Prof Jeffrey V. Lazarus, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies…

27. Dezember 2017 | Hepatitiden

Direct-acting interferon-free therapies and reinfection among people who inject drugs

Direct-acting interferon-free therapies and reinfection among people who inject drugs Jason Grebely, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017 http://www.emcdda.europa.eu/…

27. Dezember 2017 | Hepatitiden

HCV treatment as prevention in Europe: model projections and impact of current and scaled-up treatment rates

HCV treatment as prevention in Europe: model projections and impact of current and scaled-up treatment rates Hannah Fraser, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017 http…

27. Dezember 2017 | Hepatitiden

Access to HCV treatment under special consideration in prison

Access to HCV treatment under special consideration in prison Gabriele Fischer, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017 http://www.emcdda.europa.eu/system/files/attachme…

Weitere
akutelle Informationen
zu den Themengebieten